India

“Covaxin” a great hope for countrymen waiting anxiously to get rid of Dreaded pandemic

In view of the rapid spike in Covid 19 cases in India and the national tally having crossed ninety one lakh numbers with 1 lakh 33 thousand fatalities, especially during the onset of the winter season and the recent Deepawali n Dussehra festivals with Christmas and New year festival in the offing shortly, the human trials on five Covid 19 vaccines are in progress in India with two mainly undergoing third stage human trials ( allegedly) likely to be out by the first month of the next year in 2021 as being hoped for, by various governmental assurances day in and day out.

However, according to the latest news the third clinical human trials of Hyderabad’s company Bharat Biotech company has commenced in Haryana the other day with Haryana’s minister of Home affairs Anil Vij accepting the first shot of Covid 19 vaccine candidates COVAXIN.

In India this vaccine is to be injected in over twenty five thousand eight hundred human beings being its third and final human trial after successfully executing two human trials in India.

Out of the total five Covid 19 candidates the human trial of two vaccines are in progress likely to be in our midst in the coming few months with entire country likely to be injected in the entire country by anti Covid next winters say various sources.

The prime minister Narendra Modi had on Saturday held an important meeting to review India’s vaccination strategy and the way forward. According to him important issues related to the progress of the vaccine development, regulatory approvals and procurement were discussed tweeted PM Narendra Modi.

The third human trial of COVAXIN of Bharat biotech, Hyderabad will be conducted on total twenty eight thousand people in different parts of the country in 21 centres reveal news reports.

Covaxin candidate vaccine undergoing the third phase trial with best human clinical results in phase one, two stage trials has been a joint exploration of Bharat Biotech Hyderabad and India Council of Medical Research.

According to the member health Niti Ayog and the chief of the national task force on Covid 19 India Dr. V. K Paul Indian has mainly three vaccine candidates for Covid 19. They are ChAdOx1, invented n developed by Oxford University United Kingdom and jointly manufactured by Serum Institute of India, Pune and AsteraZeneca, whereas the Bharat Biotech Hyderabad, Covaxin jointly developed by ICMR, of union govt and the third being the Zycov D by by Zydus Cadilla.

According to the ET Healthworks the developments on the vaccine came a day after the National Expert Group on Vaccine Administration met five domestic Covid vaccine manufacturers to review the clinical trial stages of these vaccine candidates.

The manufacturers included two whose products are not yet in the clinical trial stage in India.

While the Hyderabad’s Bharat Biotech has started its third clinical human trial of its Covid 19 vaccine candidates in full swing, several vaccine candidates globally have exhibited extremely promising results and have come to its advanced stages likely to launch them shortly.

As per the various news updates these successful vaccines are : Moderna, Pfizer, Sputnik V of Gemalaya Russia , Covaxin and Johnson n Johnson etc. The US food and drugs administration is already giving permission to its Covid 19 vaccine candidates shorty which have shown extraordinary 95% efficacy results such as Pfizer in collaboration with BioNtech of Germany etc.

The CMD of Serum Institute Poonawala had already given clear indications of the Covid 19 vaccine coming in the market within few months from now raising high hopes of countrymen.

In a tweet by Covid 19 Vaccine Alerts CEO Seram Institute of India’s CEO Adar Poonawala had disclosed that Oxford Covid 19 vaccine should be available for healthcare workers n elderly people by February 2021 n by April 2021 for general public . It will be prized at a maximum of Rs. 1000 for two necessary doses.

The India’s Bharat Biotech manufactured domestically with Indian Council of Medical Research namely COVAXIN WHICH HAS ALREADY COMMENCED ITS PHASE THREE HUMAN TRIALS is being considered as more than sixty percent effective as per the statement of the President of Quality Operations of Hyderabad’s Bharat Biotech likely to acknowledge the official approval of WHO,CDSCO of India n USFADO.

Keeping in view the rapid spike in Covid 19 infections reaching to ninety one lakh numbers though recovery rate is quite satisfying at 92.5% but mortalities are really disturbing n shocking with India still maintains its second position after America globally. Prime minister Narendra Modi’s intervention in through a significant meeting to review India’s vaccination strategy in order to procure it at the earliest for the well-being of countrymen has indeed raised high hopes as people have n are losing their near n dear ones every single day with no hope in sight for the present to get rid of this dreaded pandemic.

Tags

Sunil Negi

Sunil Negi is a senior journalist and president of Uttarakhand Journalists Forum ( Regd). He usually writes on socio political subjects and have been contributing articles in print media for the last several years. Mr. Sunil Negi had been felicitated by All India Achievers conference's Pride of India and excellence awards apart from several other recognitions. He has translated a book on ecological disaster of Uttarakhand of June 2013 and edited and published two editions of Uttaranchal's Who's Who.

Related Articles

Back to top button
Close